AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 18 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A potential anti-cancer vaccine has been shown safe at up to 10 times the required dose in rhesus macaques when administered intravenously, and further trials in humans may be warranted, say researchers at Avax Technologies.
About half of cancers overexpress the p53 gene, and development of a vaccine targeting it has been successful in the mouse model, when administered intravenously. Its potential safety in humans has been questioned, however, due to fears of stimulating a damaging autoimmune response.
Brigitte Rosenwirth and colleagues at Avax Technologies, Rensselaer, New York, immunized rhesus macaques with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207), which in previous studies had prevented growth of p53-overexpressing tumors in mice.
The researchers gave macaques up to 10 times the proportional dose in humans, with apparently no ill effect ("Safety and immunogenicity of ALVAC wild-type human p53 (VCP207) by the intravenous route in rhesus macaques," Vaccine, 2001;19(13-14):1661-1670).
"Serologic markers ...
Source: HighBeam Research, Canarypox Virus Vector For IV p53 Vaccine Delivery Safe In Rhesus...